David Michael Williams - 10 Feb 2022 Form 4 Insider Report for Merck & Co., Inc. (MRK)

Role
EVP,Chief Info&Digital Officer
Signature
/s/ Kelly E. W. Grez as Attorney-in-Fact for David Michael Williams
Issuer symbol
MRK
Transactions as of
10 Feb 2022
Net transactions value
+$55,484
Form type
4
Filing time
14 Feb 2022, 10:13:56 UTC
Previous filing
11 Feb 2022
Next filing
28 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRK Common Stock Options Exercise $91,989 +1,202 +19% $76.53 7,421 10 Feb 2022 Direct
transaction MRK Common Stock Tax liability $36,505 -477 -6.4% $76.53 6,944 10 Feb 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRK Restricted Stock Unit Options Exercise $0 -1,202 -50% $0.000000 1,205 10 Feb 2022 Common Stock 1,202 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Holdings include shares acquired in dividend reinvestment transactions.
F2 Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
F3 Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.
F4 These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 2/10/2021, 2/10/2022 and 2/10/2023.

Remarks:

See Exhibit 24 - Power of Attorney